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Background: Tramadol and codeine are metabolized by CYP2D6 and are subject to drug–gene and drug–
drug interactions. Methods: This interim analysis examined prescribing behavior and efficacy in 102 indi-
viduals prescribed tramadol or codeine while receiving pharmaco-genotyping as part of the INGENIOUS
trial (NCT02297126). Results: Within 60 days of receiving tramadol or codeine, clinicians more frequently
prescribed an alternative opioid in ultrarapid and poor metabolizers (odds ratio: 19.0; 95% CI: 2.8–160.4)
as compared with normal or indeterminate metabolizers (p = 0.01). After adjusting the CYP2D6 activity
score for drug–drug interactions, uncontrolled pain was reported more frequently in individuals with re-
duced CYP2D6 activity (odds ratio: 0.50; 95% CI: 0.25–0.94). Conclusion: Phenoconversion for drug–drug
and drug–gene interactions is an important consideration in pharmacogenomic implementation; drug–
drug interactions may obscure the potential benefits of genotyping.
First draft submitted: 20 December 2018; Accepted for publication: 6 February 2019; Published online:
20 February 2019
Keywords: adverse side effects • CYP2D6 • IGNITE • INGENIOUS • pharmacogenetics; opioids • pharmacogenomics
• phenoconversion
Tramadol and codeine are widely used drugs in the treatment of mild to moderately severe pain. However, the
analgesic effect of tramadol and codeine is highly variable. Both are prodrugs that are converted into active
metabolites by cytochrome P450 2D6 (CYP2D6) [1]. The CYP2D6 gene is highly polymorphic, with over 100
allelic variants (www.pharmvar.org/gene/CYP2D6). A well-known activity score system facilitates conversion of
CYP2D6 genotype information into numeric scores associated with ultrarapid (UM), normal, reduced and poor
metabolizer (PM) phenotypes [2]. It follows that CYP2D6 genetic variations and drug–drug interactions (DDIs)
are important determinants of the variable effects of tramadol and codeine. Indeed, based on an individual’s
CYP2D6 metabolic activity, dosage and usage guidelines for both drugs have been promulgated by the Dutch
Pharmacogenomic Working Group (DPWG) and the Clinical Pharmacogenomics Implementation Consortium
(CPIC) [3–5]. For example, PM of CYP2D6 are expected to have reduced efficacy of codeine and tramadol, placing
them at increased risk for insufficient pain relief. Conversely, ultrarapid metabolizers may be at higher risk of
toxicity. The CPIC and DPWG recommend avoidance of codeine and tramadol in individuals with PM and UM
metabolism phenotypes.
Pharmacogenomic implementation efforts have sought to test the utility and collective evidence supporting
genotype-guided recommendations in the clinical environment [6–9]. However, complexities specific to opioids exist
because these drugs are prescribed for heterogeneous indications including multiple severities of acute and chronic
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pain [10]. As the deleterious consequences of the opioid epidemic are beginning to be understood [11], medical
societies have called for caution in the prescription of opioids [12,13]. Nonetheless, a consistent segment of the
population remains unsatisfied with pain control [14–17]. Perhaps as a result of increased guidance or scrutiny, opioid
prescribing has actually plateaued since 2010 in many clinical specialties [18]. The use of pharmacogenomic-guided
opioid therapy may assist prescribers in determining which patients will respond as expected to tramadol and
codeine, thereby reducing adverse events and maximizing efficacy [19–21]. The genotyping may further serve to
reinforce or validate a patient’s complaint of uncontrolled pain.
Given the prolific usage of opioids, integration of algorithms into the electronic health record (EHR) has proven
essential to ensure clinicians are able to access genotype-guided dosing recommendations expediently; however, these
EHR algorithms may not simultaneously account for DDIs [22]. The advantages of pheno-converting a drug–gene
based activity score to one that incorporates both drug–gene and DDIs have garnered increasing recognition [2,23–
28]. Phenoconversion of CYP2D6 activity, often driven by nongenetic factors like concomitant medication use, can
have a significant impact on the interpretation of pragmatic pharmacogenomic clinical trial outcomes since these
trials may include patients taking inhibitors [28]. The CPIC currently provides guidance on the appropriate degree
of reduction in activity score for strong and moderate inhibitors [4].
The ongoing Indiana Genomics Implementation: An Opportunity for the Underserved (INGENIOUS) trial
(NCT02297126) is a member program within the Implementing Genomics in Practice (IGNITE) Network [29–
31]. A description of the trial and the clinical support has been previously reported [6] and is summarized in the
methods. As a pragmatic trial, INGENIOUS builds upon pharmacogenomic discoveries that have been culled
from tightly controlled clinical efficacy trials, testing the clinical effectiveness of these relationships in a routine
practice setting. We present an interim analysis of tramadol and codeine prescribing behavior and efficacy from
the intervention arm of the INGENIOUS trial, comparing subjects (who have received genotyping) based on
their predicted metabolizer status. We hypothesized that subjects with actionable genotypes (having drug–gene or
drug–drug interactions) would be more likely to undergo changes in prescribing behavior as compared to those with
nonactionable genotypes. Additionally, we tested whether the presence of uncontrolled pain would correspond to
an individual’s metabolism activity score and whether the presence of DDIs would affect both prescribing behavior
and efficacy. We test these hypotheses in the ensuing analysis.
Subjects & methods
INGENIOUS trial
The INGENIOUS trial (NCT02297126) enrolls eligible subjects who receive a new prescription of one of
27 common medications (Supplementary Table 1). Tramadol and codeine are included among the 27 drugs
that precipitate enrollment. Subjects undergo either standard care (the control arm) or pharmaco-genotyping
(intervention arm) [6]. Both arms are followed for 1 year after enrollment; outcomes include composite healthcare
costs and adverse event incidence. Within 7 days of enrollment, genotype-guided dosing recommendations in
alignment with the DPWG or CPIC guidelines are sent to the prescriber and are uploaded as a searchable
document within the EHR. An adjudication committee reviews genotypes and medication lists for participants to
ensure prescribers receive actionable results (including drug–drug interactions) and to identify incidental findings [6].
The healthcare provider may elect to continue the current therapy or may alter drug selection or dosage based on
the pharmacogenomic test results and recommendations. Additional input from clinical pharmacology consultants
is available upon request [32].
New prescriptions were identified through an electronic algorithm, and subjects are recruited from among patients
of providers in two large health systems (Indiana University Health and Eskenazi Health) spread across the state
of Indiana [33,34]. INGENIOUS has broad inclusion criteria, and clinicians can choose whether or not to follow
its recommendations. According to the Pragmatic Explanatory Continuum Indicator Summary 2 (PRECIS-2)
tool [35], INGENIOUS is highly pragmatic, minimizing study-related measures that would impact usual care.
Subjects
Subjects were included in this interim analysis if they met the following criteria: they were enrolled in the intervention
arm of the INGENIOUS trial prior to 1 September 2017, gave informed consent, had a blood or saliva specimen,
and they received at least one dose of tramadol or codeine as a primary or secondary medication that precipitated
the delivery of pharmaco-genotyping results. The indications for tramadol or codeine included both acute and
chronic pain. A total of 176 subjects met these criteria. A primary precipitant enrollment was defined as a new
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prescription of tramadol or codeine prompting entry into the trial (N = 172). A secondary precipitant medication
enrollment refers to an individual enrolled after a new prescription of a nonopioid (e.g., clopidogrel), but who
then received a new prescription of tramadol or codeine within 1 year (N = 4). One subject received tramadol as
a primary precipitating medication and acetaminophen with codeine as a secondary precipitating medication and
was analyzed based on receiving tramadol. All subjects included in the present analysis were from the intervention
arm; our comparisons are made between groups of genotyped subjects.
Subjects were excluded from the analysis if: the patient never received a tramadol or codeine prescription,
it could be confirmed that the patient never filled or took the trigger medication despite a prescription, the
precipitating medication was for a nonpain indication such as cough, the patient’s sample failed genotyping, the
patient had a positive urine drug screen (UDS) during follow-up or the patient received a simultaneous and
concurrent prescription of a second opioid (e.g., tramadol and oxycodone were prescribed on the same day). The
latter exclusion was used because it was not possible to separate the effects of the two drugs.
Genotyping
The DNA was extracted from whole blood or saliva using the Qiagen EZ1 XL (MD, USA) according
to manufacturer’s recommendations. Genotyping of CYP2D6 was performed by using PCR and Taqman R©
(ThermoFisher, MA, USA) allele discrimination in a custom designed microarray for the following variants:
CYP2D6*2 (c.2850C>T and c.4180G>C), CYP2D6*3 (c.2549delA), CYP2D6*4 (c.1846G>A and c.100C>T),
CYP2D6*6 (c.1707delT),CYP2D6*7 (c.2935A>C),CYP2D6*9 (c.2615 2617delAAG),CYP2D6*10 (c.100C>T
and c.4180G>C), CYP2D6*17 (c.1023C>T), CYP2D6*29 (c.3183G>A), CYP2D6*41 (c.2988G>A). Copy
number (e.g, 0, 1, 2, 3 or more) of CYP2D6 was performed using the  Ct method (ThermoFisher). Subjects
were reported as an indeterminate phenotype (i.e., metabolizer status), if a duplication/multiplication was observed
and it was not possible to determine which allele was duplicated/multiplicated.
Prescribing behavior outcomes
The INGENIOUS trial does not have prespecified outcomes to measure prescribing behavior with regard to
tramadol and codeine. The outcomes below were adjudicated retrospectively by manual search of each participant’s
Indiana University Health or Eskenazi Health system EHR data by two clinically trained investigators. All available
follow-up data were utilized. As an interim analysis, all included subjects were followed for a minimum of 90 days
postopioid prescription. The maximum follow-up was 1 year for those who had completed the INGENIOUS
study. Comparisons were made between individuals with actionable (ultrarapid, intermediate/reduced or poor)
and nonactionable (normal/extensive, indeterminate) metabolizer status. The rationale for these comparisons lies
in the provider recommendations that the INGENIOUS trial generates in the EHR, wherein no change in dose
or drug selection is recommended for either normal or indeterminate metabolizers, but changes are recommended
for ultrarapid, poor and intermediate/reduced metabolizers. An additional comparison was made using a logistic
regression model to account for the strength of recommendation. Normal and indeterminate results recommended
no change to standard therapy; intermediate/reduced metabolizer results contained moderate recommendations
regarding dosage or monitoring and UM or PM results contained strong recommendations for alternative drug
selection.
Outcomes assessed included: an alternative opioid prescribed during follow-up periods of 30, 60 and 90
days, and 1 year, purposeful discontinuation of tramadol or codeine by a provider prior to the expiration or
conclusion of the prescription, a change in dose during follow-up, a refill of tramadol or codeine during follow-
up and an nonsteroidal anti-inflammatory drugs (NSAIDs) prescribed or noted in the EHR during follow-
up. Alternative opioids included hydrocodone, oxycodone, morphine, hydromorphone, and fentanyl. Alternative
opioids administered for preprocedural sedation were excluded. For example, a single dose of intravenous fentanyl
for a colonoscopy was not counted toward an alternative opioid outcome.
Efficacy & adverse event measures
All efficacy and adverse event outcomes of tramadol and codeine usage were determined retrospectively using
the EHR. The main efficacy outcome was the presence of patient reported uncontrolled pain after the initial
opioid prescription. To ascertain efficacy, two investigators reviewed each patient’s EHR data and all relevant
documentation to determine the presence of uncontrolled pain as documented by a provider. Discrete scores on a
‘pain scale’ of 8, 9 or 10 were also deemed to represent uncontrolled pain.
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Additionally, two investigators screened relevant EHR entries to determine if a participant experienced the
toxicity side effects of constipation or sedation. Reports of constipation or sedation that were not related or unlikely
to have been related to the precipitating medication were excluded.
Activity scores & drug–drug interactions
For each CYP2D6 allele variant, a value relative to the fully functional CYP2D6*1 reference allele was assigned to
construct a CYP2D6 activity score, ranging from 0 for poor to 3 for UM. The allele based contributions to the
activity score were: score of 0: *3, *4, *4xN, *5, *6, *7, *16, *36, *40, *42, *56B, score of 0.5: *9, *10, *17, *29, *41,
*45, *46, score of 1: *1, *2, *35, *43, *45xN and score of 2: *1xN, *2xN, *35xN [2]. Normal metabolizers (activity
score of 2) served as the comparator group for adverse event analyses. Indeterminate metabolizers (with *1/*4/xN
or *2/*4/xN genotypes) had unpredictable activity scores and were excluded from the efficacy and toxicity analyses.
Comparisons were made using a logistic regression model between activity and efficacy or toxicity outcomes.
Medication lists were screened to identify concomitant DDIs with CYP2D6 moderate and strong inhibitors.
According to CPIC recommendations, activity scores were adjusted to 0 with concomitant use of the strong
inhibitors paroxetine, quinidine, terbinafine, thioridazine, propafenone, fluoxetine or bupropion. For the moderate
inhibitors, duloxetine, fluvoxamine, mirabegron, cinacalcet and cimetidine, activity scores based on genotype were
divided in half and rounded down to the nearest 0.5 increment [4].
Data analysis
All data were integrated and analyzed using SAS callable SUDAAN 9.0 (RTI International, Research Triangle Park,
NC, USA) and R. Logistic regression was used to determine the significance of prescribing behavior, efficacy and
adverse events when appropriate. Sensitivity analyses were performed for indeterminate metabolizers and individuals
prescribed opioids for nonpain indications. For the cohort, odds ratios (OR) with 95% CI were calculated with
nonactionable genotypes as the reference comparator for prescribing behavior and normal metabolizers as the
reference group for efficacy and adverse events. Covariates such as age, race, gender, ethnicity and health system
were adjusted in each logistic regression. Due to the small sample size, some comparisons produced cell sizes that
violated the law of large numbers required for logistic regression, and the Fisher’s Exact Test was conducted to
determine if there were significant differences (p < 0.05).
Results
Of 764 subjects enrolled in the INGENIOUS trial intervention arm, 102 met inclusion criteria for this analysis
based on a new prescription of tramadol or codeine. Table 1 describes the demographic information of the subjects
included in the analysis. The mean age was 51.5 years, and 64.7% of subjects were female. The majority of
individuals were enrolled following outpatient or emergency department prescriptions of either opioid. A number
of exclusion criteria were employed (Figure 1). Patients, who had a genotype failure, neither filled nor took
the precipitating medication or received the medication for a nonanalgesic purpose (e.g., codeine for cough)
were excluded. Patients, who had a positive UDS during follow-up, were removed from the analysis because a
positive test for illicit substances skewed prescribing behavior by prompting clinicians to discontinue the opioid
and to avoid prescribing future alternate opioids. Dual opioid prescriptions were common as 28 of 142 (20%)
enrolled individuals received a second new opioid prescription on the same day as their initial tramadol or codeine
prescription. Common rationales for this prescribing behavior included: instructions to take different medications
according to pain severity and using one medication as a maintenance dose and another as breakthrough therapy.
Participants, who received planned concurrent opioid analgesia, were excluded from the analysis because the
effects of each drug could not be differentiated. Supplementary Table 2 includes demographic information for all
individuals who were enrolled, genotyped and received the precipitating opioid (N = 142). No significant difference
was noted between those included (N = 102) and those excluded (N = 40) from the final analysis.
Table 2 describes the distribution of predicted phenotypes in the participants included in the final analysis. A
genotype was considered actionable if the laboratory result report contained a recommendation for a change in dose
or agent. Reports for UM and PMs contained strong recommendations for alternate agent selection or dose change,
whereas reports for reduced metabolizers contained moderate recommendations for a dose change. A portion of
the cohort had DDIs at the time of enrollment (24.5%). The trial’s adjudication committee alerts prescribers to
the presence of drug–drug–gene interactions upon the initial prescription. Most participants (65.7%) concurrently
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Table 1. Demographics.
Number of participants N = 102
Gender, N (%)
– Female 66 (64.7%)
– Male 36 (35.3%)
Age, mean (range) 51.5 years (21–95 years)
– Ethnicity, N (%)
– Hispanic or Latino 2 (2%)
– Not Hispanic or Latino 95 (93%)
– Prefer not to answer 5 (5%)
Race, N (%)
– Asian 1 (1.0%)
– Black or African–American 34 (33.3%)
– White 65 (63.7%)
– Other or unreported 2 (2.0%)
Patient location
– Emergency department 2 (2%)
– Inpatient 6 (6%)
– Outpatient 94 (92%)
Indication:
– Pain 102 (100%)
764 genotyped subjects between 6/15/2015 – 8/31/2017
Tramadol (n = 139) or codeine (n = 33) target med
or secondary trigger medication (n = 4)
n = 176
Non-opioid target medication


























Never received opioid n = 22
Non-pain indication n = 11
Genotype failure n = 1
Included in analysis
n = 102
Exclude n = 40
UDS positive n = 12
Concurrent opioid n = 28
Ultra-rapid metabolizers n = 5
n = 0 with DDls
n = 5 without DDI
Normal/Indeterminate metabolizers n = 62
Normal metabolizers n = 53
n = 11 with DDls
n = 42 without DDI
Indeterminate metabolizers n = 9
n = 4 with DDls
n = 5 without DDls
Reduced/poor metabolizers n = 35
Reduced metabolizers n = 32
n = 10 with DDls
n = 22 without DDls
Poor metabolizers n = 3
n = 0 with DDI
n = 3 without DDls
Figure 1. Inclusion and exclusion criteria for the 102 participants in the analysis. All participants were enrolled prior to 31 August 2017.
Primary trigger medications are medications prompting enrollment. Secondary trigger medication indicates a prescription for tramadol or
codeine within 1 year of a subject’s trial enrollment for a nonopioid medication.
DDI: Drug–drug interaction with a CYP2D6 inhibitor; UDS: Urine drug screen.
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Table 2. Clinical characteristics.
Category N (%)
Metabolizer status inferred from genotype
– Ultrarapid 5 (4.9%)
– Normal 53 (52.0%)
– Indeterminate 9 (8.8%)
– Reduced/intermediate 32 (31.3%)
– Poor 3 (2.9%)
Genotype status
– Actionable 40 (39.2%)
– Nonactionable 62 (60.8%)
Drug–drug interactions
– Total 25 (24.5%)
– Fluoxetine† 6 (5.9%)
– Buproprion† 5 (4.9%)
– Paroxetine 5 (4.9%)
– Duloxetine† 10 (9.8%)
– Mirabegron 1 (1.0%)
NSAID use
– Total 67 (65.7%)
– Ultrarapid or poor 5 (62.5%)
– Reduced 22 (68.8%)
– Normal/indeterminate 40 (64.5%)
†Two drug–drug interactions involved multiple CYP2D6 inhibitors including buproprion with either fluoxetine or duloxetine.
NSAID: Nonsteroidal anti-inflammatory drug.
Table 3. Logistic regression association between prescribing behavior and genotype.
Variable (A)
Poor/ultrarapid
N = 8 (%)
(B) Reduced
N = 32 (%)
(C) Normal/
indeterminate






Alternate opioid prescribed by 30 days (Y) 3 (38) 3 (9) 3 (5) 15.1 (1.8–161.3) 2.3 (0.4–13.7) 0.04
Alternate opioid prescribed by 60 days (Y) 4 (50) 4 (12) 3 (5) 19.0 (2.8– 160.4) 2.9 (0.6– 16.2) 0.01
Alternate opioid prescribed by 90 days (Y) 4 (50) 8 (25) 7 (11) 9.5 (1.7– 57.3) 2.6 (0.8– 8.8) 0.03
Alternative opioid prescribed during follow-up
(Y)†
5 (63) 11 (34) 17 (27) 4.6 (0.9–25.9) 1.5 (0.6– 4.0) 0.16
Discontinuation of tramadol or codeine during
follow-up (Y)†
7 (88) 12 (38) 15 (24) 24.7 (3.6– 503.1) 1.9 (0.7– 5.1) 0.002
Dose change (Y)† 1 (13) 4 (13) 13 (21) 0.6 (0.03– 4.6) 0.7 (0.2– 2.2) 0.79
Refill prescribed (Y)† 0 (0) 14 (44) 30 (48) 0 (NA)‡ 0.9 (0.3– 2.2) 0.01
†All available follow-up (up to 1 year) was used to determine the outcome.
‡95% CI not available due to sample size.
OR: Odds ratio; Y: Yes or positive outcome.
All p-value calculations are based on a multivariate logistic regression model.
used prescribed or over-the-counter NSAIDs either at the time of enrollment or during the follow-up period. No
significant difference in NSAID use was identified between groups stratified by metabolizer status (Table 2).
A significant association between genotype actionability and prescribing behavior was identified (Table 3).
Individuals were grouped according to genotype-based recommendations. Within 30 days of an initial tramadol
or codeine prescription, individuals with an actionable genotype were prescribed an alternate opioid with greater
frequency than those with a nonactionable genotype (p = 0.04). Analogous observations were made at 60 and 90
days, but not with up to 1 year of follow-up. The frequency of a provider-initiated discontinuation of a precipitating
medication was also measured. Only prescriptions that were stopped by a provider prior to expiration or completion
of the prescription duration were counted. Participants with actionable genotypes were more likely than those with
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N = 25 (%)
(B) Reduced
N = 30 (%)
(C) Normal/
indeterminate






Alternate opioid prescribed by 30 days (Y) 6 (24) 0 (0) 3 (6) 4.6
(NA)†
0 (NA)† 0.01
Alternate opioid prescribed by 60 days (Y) 7 (28) 1 (3) 3 (6) 4.9 (1.2–26.1) 0.6 (0.03–5.0) 0.003
Alternate opioid prescribed by 90 days (Y) 7 (28) 6 (20) 6 (13) 3.4 (0.9–13.4) 1.8 (0.4–3.3) 0.19
Alternative opioid prescribed during follow-up
(Y)‡
13 (52) 8 (27) 12 (26) 3.6 (1.3–11.20 1.3 (0.4–4.1) 0.054
Discontinuation of tramadol or codeine during
follow-up (Y)‡
13 (52) 11 (37) 10 (21) 5.0 (1.7–16.7) 2.8 (0.9–0.1) 0.01
Dose change (Y)‡ 3 (12) 4 (13) 11 (23) 0.5 (0.1–1.8) 0.7 (0.2–2.6) 0.58
Refill prescribed (Y)‡ 6 (24) 14 (47) 23 (49) 0.3 (0.1–0.9) 1.1 (0.4–3.1) 0.046
†95% CI not available due to sample size.
‡All available follow-up (up to 1 year) was used to determine the outcome.
OR: Odds ratio; Y: Yes or positive outcome.
All p-value calculations are based on a multivariate logistic regression model.
Table 5. Association of adverse events and inefficacy with according to activity score scale.
Variable Drug–gene model
OR (95% CI)
per unit activity score
p-value DGI + DDI model
OR (95% CI)
per unit activity score
p-value
Uncontrolled pain (Y) 0.929 (0.44–1.93) 0.84 0.50 (0.25–0.94) 0.03
DGI + DDI model: Drug–gene interaction and drug–drug interaction logistic regression model; OR: Odds ratio; Y: Yes or positive outcome.
nonactionable genotypes to have their tramadol or codeine actively stopped (p = 0.002). No significant difference
in opioid dose change was associated with genotype (p = 0.79). However, normal and indeterminate metabolizers
were more likely to be provided a refill by their providers in the available follow-up period of up to 1 year (p = 0.01).
Similar associations were identified after metabolizer status was adjusted for DDIs (Table 4). After accounting
for DDIs, 18 participants were reclassified as PMs. Individuals with actionable metabolizer phenotypes were more
likely to be prescribed an alternate opiate at 30, 60 days or have their precipitating medication discontinued during
follow-up. Subjects with actionable genotypes also had a reduced refill frequency (p = 0.046). No statistically
significant differences for alternate opioid prescriptions within 90 days or during all follow-up were found between
actionable and nonactionable genotypes across the entire drug–gene and drug–drug interaction (DGI + DDI)
logistic regression model. Two sensitivity analyses for prescribing behavior were performed by either including
individuals with nonpain indications (N = 11) or excluding indeterminate metabolizers (N = 9). Similar results
were found in both sensitivity analyses. When including nonpain opioid indications, individuals with actionable
genotypes were more likely to have their tramadol or codeine discontinued (p = 0.03) or an alternate opioid
prescribed in the first 30 days (p = 0.04). When removing indeterminate metabolizers from the analysis, the
actionable individuals were still more likely to have their opioid discontinued (p = 0.02) or an alternate opioid
prescribed (p = 0.004).
Associations between metabolizer status and efficacy were examined (Table 5). The incidence of uncontrolled
pain reported in the EHR during follow-up was 22.7%. Individuals were assigned an activity score according to two
models: genotype alone in a drug–gene interaction model (DGI) or genotype adjusted for DDIs in the combined
DGI + DDI model. Indeterminate metabolizers in whom an activity score could not be assigned were excluded.
According to the DGI model, no significant association between activity score and uncontrolled pain was found.
In the DGI + DDI model, a significant association with reported pain was identified. For every 1 unit increase
in activity score, the odds ratio of reporting uncontrolled pain was 0.50 (95% CI: 0.25–0.94). Among individuals
with a DDI-adjusted activity score of 0.5 or less, 40.7% complained of uncontrolled pain. Among individuals
with activity score of 1 or greater, only 15.7% relayed similar complaints. The incidence of adverse events such
as constipation and sedation was examined according to both models, but reporting of these adverse events in the
EHR was low. No significant association between activity score and either constipation or sedation was identified.
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The apparent acceptance rate by clinicians of the pharmacogenomic-guided dose recommendations was 81.8%
(45 of 55) in subjects with actionable phenotypes (as evidenced by dose changes, discontinuation or alternate
opioid prescriptions). The high acceptance rate precluded a statistical comparison of uncontrolled pain, stratified
according to acceptance and nonacceptance. In summary, small but important differences were noted when clinical
information on DDIs is added to genotype information.
Discussion
In this study, we present an interim analysis of the prescribing behavior and efficacy associated with tramadol
and codeine use, as gleaned from the INGENIOUS trial. The two major findings of our study are: genotype
and metabolizer status are associated with differential prescribing behavior, and genotype alone was insufficient to
predict opioid efficacy (pain control) without consideration of concomitant drug–drug interactions. At the onset,
the INGENIOUS trial did not contain prespecified outcomes related to pain control for codeine or tramadol.
Although the INGENIOUS investigators contacted each provider with regard to participants with drug–gene and
drug–drug interactions, prescribers are free to adjust dosing as they see fit. Thus, the cause and effect relationship
between genotyping and prescribing behavior cannot be completely ascertained. Specifically, we cannot distinguish
whether the provider changed a prescription based on the genotyping test or whether the genotype simply reflects
the natural history of efficacy and toxicity, which would have prompted alterations in prescriber behavior.
This pragmatic study builds upon a strong foundation of pharmacokinetic and clinical efficacy studies. Several
preceding investigations have illustrated the relationships between CYP2D6 genotype, tramadol pharmacokinetics
and tramadol efficacy [36–39]. These collective data ultimately culminated in DPWG guidelines recommending
genotype-guided tramadol therapy [40]. Controlled studies of codeine that relate metabolizer status to metabolite
concentrations and efficacy [41–43], as well as several high profile case studies [44,45], have led to the curation of CPIC
guidelines for pharmacogenomic-guided dosing of codeine [4]. Corroborating our results, a prior study revealed
that implementation of pharmacogenomics in a large health system impacted prescribing behavior of codeine for
children with sickle cell disease [8].
When comparing those with and without actionable genotypes, our analysis revealed that healthcare providers
displayed different prescribing behavior. Ultrarapid, poor and intermediate/reduced metabolizers were more likely
to receive an alternate opioid or to have their prescription discontinued as compared with normal or indeterminate
metabolizers. These same individuals were less likely to receive a refill than normal metabolizers were. Most
practitioners never documented their rationale in the clinical notes for dose changes, medication discontinuations
or refills. Therefore, during retrospective adjudication, it was not possible to determine whether prescribing behavior
was a surrogate for undocumented adverse events or inefficacy. Further, adverse events were infrequently recorded
and almost never coded as a diagnosis. Similarly, pain control was not a defined end point and it is possible
that inefficacy was under-reported. After adjusting activity score for DDIs, uncontrolled pain was found more
frequently reported in individuals with reduced CYP2D6 activity. This finding was obscured when only the
drug–gene model was implemented and speaks to the importance of phenoconversion for DDIs. A future aim
is to conduct a full analysis of all participants when the INGENIOUS trial follow-up concludes, including a
comparison between those who were genotyped and those who were randomized to the control arm and those who
were randomized to the intervention arm but were not genotyped because they could not be reached or declined
to provide informed consent. This interim analysis based on a manual EHR search will help to inform a more
comprehensive bioinformatics approach to evaluate tramadol and codeine outcomes.
There are significant limitations in this investigation. Foremost among these limitations is the small sample size
and the decision to forego an intention-to-treat comparison. In INGENIOUS, 176 individuals were consented in
the intervention arm after a tramadol or codeine trigger medication, but only 102 were included in this study’s
final analysis. The pragmatic nature of INGENIOUS allowed for broad inclusion criteria. The EHR’s automated
enrollment request was prompted by a prescription, but upon chart review there was evidence to confirm that 22
of the 176 patients, who consented to genotyping, never filled their prescription or the prescription was canceled
immediately. These circumstances were eliminated after one of the two health systems adopted a new EHR. The
trial protocol adapted, enrolling subjects only after they filled their prescription. A second limitation is that efficacy
is not independent of prescribing and may be impacted by changes in prescribing behavior. In order to disentangle
this inter-relationship, the sequence of events matters. In most cases, the genotyping data were provided 7 days
after the precipitating opioid prescription, suggesting that the second prescribing action taken during follow-
up may have been in response to inefficacy or toxicity. If the change was in response to inefficacy or toxicity,
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rather than providers accepting our initial recommendations, this would also support the value of implementing
pharmacogenetic genotyping to improve therapy outcomes.
Subjects with positive UDS tests and concurrent opioid therapy were excluded from the analysis. An opioid
prescription was universally discontinued in individuals who had a positive UDS, and the patients were referred to
a pain management service. Because the outcomes we measured included pain control and prescribing behavior,
we also excluded the planned use of concurrent opioid therapy. Given the small sample size, response to UDS
tests and concurrent opioid therapy may have masked any associations with genotype or drug–drug interactions.
However, these considerations also become important in the planning of future trials, which test the impact of
pharmacogenomic-guided dosing on pain control or opioid adverse events. Two deaths were noted during the
follow-up period but were determined to be unrelated to tramadol or codeine use.
The opioid epidemic has been associated with an increase in adverse drug effects [11,46], but recognition of this
crisis has also heightened awareness of the variability in response to these medications [18,47]. State laws continue to
evolve surrounding the prescribing of opioids. Beginning July 2017, a new Indiana state law (SEA 226) required
additional documentation if providers intended to prescribe an opioid for more than 7 days duration in any adult
patient receiving a first-time prescription [48]. It is likely that moving forward, this legislation will have a greater
impact on prescribing behavior and will need to be considered in future trial protocol development.
Future perspective
This investigation supports the findings of prior studies showing a relationship between genotype, prescribing
behavior and opioid efficacy. In the USA, a major challenge to the advancement of pharmacogenomics is the level of
evidence supporting payer reimbursement. Due to their greater applicability to the real-world setting, it is suggested
that results from pragmatic trials have a capacity to inform policy-making processes [49,50]. The understanding of a
patient’s pharmacogenomic response profile furnishes a healthcare provider with vital information that will guide
therapeutic decisions [51,52]. Incorporation of genotype biomarkers has the potential to improve the utility and
efficacy of current strategies and to guide the development of new approaches for pain management [52,53]. However,
knowledge of pharmacogenomic results alone is insufficient to accurately predict metabolizer status phenotypes.
Clinicians must remain vigilant for DDIs in order to select appropriate drugs and dosages. Increased sophistication
of computer decision support tools may aid clinicians in reconciling pharmacogenomics and DDIs, but until these
tools are broadly implemented, continued awareness is required. In addition, since many patients see healthcare
providers from multiple healthcare systems, pharmacogenomic results must be shared across healthcare systems,
or a system is needed for the patients to provide the pharmacogenomic information at the provider encounters.
This interim study lays the foundation for future investigations, which examine EHR data for adverse events and
clinical outcomes within the INGENIOUS trial. The IGNITE Network and the INGENIOUS trial continue to
contribute to the clinical evidence required to support pharmacogenomic implementation.
Summary points
• The INGENIOUS trial is a pragmatic implementation trial and part of the IGNITE network, which aims to test the
real world impact of pharmacogenomic testing outside of a tightly controlled environment.
• We tested whether providers would change prescribing behavior with regard to opioids for subjects with
actionable genotypes as compared with those with nonactionable genotypes and whether efficacy measures such
as uncontrolled pain would correspond to an individual’s metabolism activity score, with and without
consideration of drug–drug interactions.
• CYP2D6 genotype and metabolizer status were associated with differential prescribing behavior by clinicians.
• Genotype alone was insufficient to predict opioid efficacy without including phenoconversion for concomitant
drug–drug interactions.
• This interim study lays the foundation for future investigations, which examine electronic health record data for
adverse events and clinical outcomes of pharmacogenomic implementation.
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